Eagle Boston Investment Management Inc. Purchases 4,083 Shares of Mednax, Inc (MD)

Eagle Boston Investment Management Inc. boosted its position in shares of Mednax, Inc (NYSE:MD) by 2.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 195,719 shares of the company’s stock after acquiring an additional 4,083 shares during the period. Eagle Boston Investment Management Inc. owned 0.21% of Mednax worth $8,666,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Nordea Investment Management AB increased its stake in shares of Mednax by 4.8% in the third quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock worth $100,198,000 after acquiring an additional 106,883 shares during the period. South Dakota Investment Council boosted its holdings in Mednax by 56.3% during the third quarter. South Dakota Investment Council now owns 79,400 shares of the company’s stock worth $3,424,000 after buying an additional 28,600 shares in the last quarter. American International Group Inc. boosted its holdings in Mednax by 0.6% during the third quarter. American International Group Inc. now owns 195,583 shares of the company’s stock worth $8,434,000 after buying an additional 1,263 shares in the last quarter. TimesSquare Capital Management LLC boosted its holdings in Mednax by 1.8% during the third quarter. TimesSquare Capital Management LLC now owns 574,100 shares of the company’s stock worth $24,755,000 after buying an additional 10,000 shares in the last quarter. Finally, MUFG Securities EMEA plc purchased a new stake in Mednax during the third quarter worth $12,289,000. Institutional investors and hedge funds own 98.48% of the company’s stock.

In related news, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the transaction, the insider now owns 35,569 shares in the company, valued at $1,524,131.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of Mednax stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the transaction, the director now owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is owned by company insiders.

Shares of Mednax, Inc (NYSE:MD) opened at $50.72 on Tuesday. Mednax, Inc has a 12-month low of $40.56 and a 12-month high of $72.13. The stock has a market cap of $4,738.96, a PE ratio of 15.47, a P/E/G ratio of 1.63 and a beta of 0.40. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37.

Mednax (NYSE:MD) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The business had revenue of $868.95 million during the quarter, compared to analysts’ expectations of $864.78 million. During the same period last year, the business earned $1.09 earnings per share. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. analysts predict that Mednax, Inc will post 3.1 EPS for the current year.

Several research firms have issued reports on MD. Citigroup decreased their price objective on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Robert W. Baird increased their price objective on shares of Mednax from $47.00 to $48.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Jefferies Group reaffirmed a “hold” rating and set a $44.00 price objective on shares of Mednax in a report on Friday, November 3rd. KeyCorp set a $51.00 price objective on shares of Mednax and gave the company a “buy” rating in a report on Wednesday, November 1st. Finally, BMO Capital Markets began coverage on shares of Mednax in a research note on Monday, October 16th. They issued a “market perform” rating and a $46.00 price target on the stock. Two analysts have rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the stock. Mednax currently has a consensus rating of “Hold” and an average target price of $54.50.

ILLEGAL ACTIVITY WARNING: “Eagle Boston Investment Management Inc. Purchases 4,083 Shares of Mednax, Inc (MD)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/05/eagle-boston-investment-management-inc-has-8-67-million-holdings-in-mednax-inc-md.html.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply